Financial Performance - Net loss for Q1 2025 was $12.9 million, or $0.36 per share, compared to a net loss of $13.0 million, or $7.76 per share, in Q1 2024[11]. - The company reported a total comprehensive loss of $12.9 million for Q1 2025, slightly down from a comprehensive loss of $12.97 million in Q1 2024[16]. - Collaboration revenue for Q1 2025 was reported at $1.451 million, compared to no collaboration revenue in Q1 2024[16]. - Total operating expenses for Q1 2025 were $17.9 million, up from $12.8 million in Q1 2024[16]. Expenses - Research and development expenses increased to $11.1 million for Q1 2025, up from $9.3 million in Q1 2024, reflecting a $1.8 million rise primarily due to a $2.7 million increase in direct costs related to other programs[9]. - General and administrative expenses rose to $6.8 million in Q1 2025, compared to $3.5 million in Q1 2024, with a $3.3 million increase mainly due to a $2.0 million rise in personnel-related expenses[10]. Cash Position - As of March 31, 2025, the company had approximately $335.1 million in cash, cash equivalents, and marketable securities, sufficient to fund operations through 2029[12]. Development and Collaboration - BioAge nominated BGE-102 as its lead development candidate for obesity, with initial Phase 1 data expected in the second half of 2025[4]. - A new strategic collaboration with Lilly ExploR&D was announced to develop therapeutic antibodies targeting novel metabolic aging targets[7]. - The company continues to advance its portfolio of novel APJ agonists for obesity, aiming to nominate a development candidate by the end of 2025[8].
Bioage Labs, Inc.(BIOA) - 2025 Q1 - Quarterly Results